BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will host an in-person and virtual analyst day in New York on Tuesday, February 10, 2026 with presentations and panels from 1:00 PM to 3:00 PM Eastern. The Company will share background and updates across its portfolio and pipeline, and outline the busine ...

Flagship Location Positioned within Tencent’s Newly Completed Headquarters, Grand Opening Planned Following Chinese New Year BREA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Reborn Coffee, Inc. (NASDAQ: REBN), a leader in the specialty coffee market, today announced continued progress in its international expansion strategy with the completion of construction for its flagship location within Tencent’s newly developed headquarters campus in Shenzhen, China. With construction now complete, Reborn Coffee expect ...

Core Viewpoint - AA Mission Acquisition Corp. announced the results of its extraordinary general meeting where proposals to amend its Articles and Trust Agreement were not approved, leading to the decision to dissolve and liquidate the company [1][3]. Group 1: Meeting Results - The proposals to extend the combination period and amend the Trust Agreement did not receive the necessary votes to pass, thus the existing Articles and Trust Agreement remain unchanged [1]. - Shareholders redeemed 24,561,733 Class A ordinary shares for a pro rata portion of the Trust Account, resulting in approximately $262,073,691 (around $10.67 per share) being removed from the Trust Account [2]. Group 2: Dissolution and Liquidation - The company plans to redeem all outstanding Class A ordinary shares effective February 13, 2026, as it anticipates not completing an initial business combination by the required deadline [3]. - The redemption price for public shares is expected to be approximately $10.67, and upon redemption, public shareholders will lose their rights as shareholders [3]. Group 3: Redemption Process - Redemption amounts will be payable upon presentation of stock certificates or other delivery of shares to the transfer agent, with beneficial owners in "street name" not needing to take action [4]. - There will be no redemption rights for the company's warrants, and initial stockholders have waived their redemption rights for shares issued before the IPO [5]. Group 4: Delisting and Termination - The company expects to file a Form 25 with the SEC to delist its securities and subsequently file a Form 15 to terminate the registration of its securities under the Securities Exchange Act of 1934 [6]. Group 5: Company Overview - AA Mission Acquisition Corp. is a blank check company incorporated in the Cayman Islands, aiming to effect a business combination primarily in the food and beverage industry [8].

Core Insights - GSI Technology announced preliminary benchmark results for its Gemini-II Compute-in-Memory processor, achieving a time-to-first-token (TTFT) of 3 seconds for multimodal large language models at the edge, with a power consumption of approximately 30 watts [1][2]. Performance Metrics - The Gemini-II processor demonstrated a TTFT of 3 seconds, which is the lowest reported for a multimodal 12B model on an embedded edge processor [2]. - Competitive platforms reported TTFTs of approximately 12 seconds on Qualcomm Snapdragon X Elite at 30W and 3 seconds on NVIDIA Jetson Thor at over 100W, indicating that Gemini-II offers superior performance at lower power levels [3]. Market Implications - The performance profile of Gemini-II is well-suited for "physical AI" markets, including drones and smart city applications, where power and thermal constraints are critical [4]. - The shift from cloud-assisted models to local inference in edge physical AI is expected to enhance latency, reliability, and operational efficiency [5]. Development and Collaboration - GSI's engineering team is focused on optimizing the responsiveness of the Gemini-II processor while collaborating with partners like G2 Tech for system integration and proof-of-concept activities [6].

Core Viewpoint - West Bancorporation, Inc. reported a significant increase in net income for 2025, reflecting strong performance and strategic management, with expectations for continued improvement in 2026 [1][2]. Financial Performance - The net income for 2025 was $32.6 million, or $1.92 per diluted common share, compared to $24.1 million, or $1.42 per diluted common share in 2024 [1]. - The fourth quarter net income was $7.4 million, or $0.43 per diluted common share, down from $9.3 million, or $0.55 per diluted common share in the third quarter of 2025 [1]. - The company declared a quarterly dividend of $0.25 per common share, payable on February 25, 2026 [1]. Balance Sheet and Asset Quality - Loans decreased by $7.2 million, or 0.2 percent, in the fourth quarter of 2025, with no credit loss expense recorded in either the fourth or third quarter [5]. - The allowance for credit losses to total loans was 1.02 percent as of December 31, 2025, compared to 1.01 percent at September 30, 2025 [5]. - There were no nonaccrual loans as of December 31, 2025, indicating strong credit quality [5][10]. Deposits and Interest Income - Deposits increased by $162.0 million, or 4.9 percent, in the fourth quarter of 2025, with a notable increase of $212.2 million, or 6.8 percent, excluding brokered deposits [5]. - The net interest margin was 2.47 percent for the fourth quarter of 2025, up from 2.36 percent in the third quarter [5]. - Net interest income for the fourth quarter was $24.2 million, compared to $22.5 million in the third quarter [5]. Efficiency and Capital Ratios - The efficiency ratio improved to 50.21 percent for the fourth quarter of 2025, down from 54.06 percent in the third quarter [5]. - The tangible common equity ratio was 6.42 percent as of December 31, 2025, compared to 6.40 percent at September 30, 2025 [5]. Year-over-Year Comparison - For the year ended December 31, 2025, net interest margin was 2.35 percent, compared to 1.91 percent for the year ended December 31, 2024 [10]. - Net interest income increased by $17.6 million in 2025 compared to 2024, primarily due to a decrease in interest expense on deposits and borrowed funds [10]. - The efficiency ratio for the year improved to 54.11 percent from 63.25 percent in 2024 [10].

Core Insights - Brazilian Rare Earths Limited (BRE) reported significant progress in the quarter ending December 31, 2025, highlighting advancements in its Amargosa Bauxite project and partnerships in the rare earth sector [1]. Group 1: Amargosa Bauxite Project - The Amargosa Bauxite project is a large-scale, low-cost direct-ship-bauxite operation with a JORC Resource estimate of 568 million tons, including 98 million tons of direct-ship-bauxite [4]. - The project is expected to generate an average EBITDA of US$102 million per annum and free cash flow of US$84 million per annum over a 17-year mine life, with an after-tax NPV8 of US$630 million and a payback period of approximately 1.2 years [4]. - The project is positioned in the lowest-cost first quartile on the global seaborne bauxite cost curve, with permitting timelines of approximately 2-3 years for comparable operations, aiming for potential development by 2028 [4]. Group 2: Strategic Partnerships - BRE has entered a long-term partnership with Carester, a specialist in rare earth processing, to support the engineering, construction, and commissioning of a rare earth separation refinery at the Camaçari Petrochemical Complex in Bahia [2][4]. - Carester will purchase BRE's heavy rare earth concentrate under a binding 10-year offtake agreement, supporting the production of approximately 150 tons per annum of separated dysprosium and terbium oxides [4]. Group 3: Financial Position and Leadership - BRE appointed John Vander Ploeg as Chief Financial Officer, bringing over 20 years of experience in finance and corporate transactions [3][4]. - As of December 31, 2025, BRE held A$162.4 million in cash, following a successful placement of 25.6 million shares at A$4.68 per share, raising A$120 million to accelerate the development of its rare earth projects [4].

SARASOTA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- INVO Fertility Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on December 3, 2025 (the “December 2025 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to a reduced exercise price of the outstanding ...

Core Viewpoint - HeartSciences Inc. has partnered with Cibolo Rural Health Networks to provide its MyoVista Insights™ ECG management platform to a network of 123 independent hospitals, enhancing ECG workflow efficiency and clinical decision-making [1][2][4]. Group 1: Company Overview - HeartSciences is a healthcare information technology company focused on advancing electrocardiography through artificial intelligence integration [1][5]. - The MyoVista Insights platform is a cloud-native ECG management system designed to improve clinical efficiency and decision-making [5]. Group 2: Partnership Details - Cibolo Health has selected MyoVista Insights as its endorsed ECG management platform for its network of independent hospitals across six states [2][4]. - The collaboration aims to modernize legacy ECG workflows, allowing physicians to interpret ECGs more quickly and efficiently [2][4]. Group 3: Technology and Benefits - MyoVista Insights provides secure, cloud-based ECG data management across various devices and file formats, supporting the integration of AI-ECG algorithms into clinical practice [3]. - The partnership aligns with Cibolo Health's mission to enhance care quality and operational efficiency while managing costs for its member hospitals [4][6].

Core Insights - Satellogic, Inc. has extended its agreement with the Government of Albania for continuous, high-frequency satellite monitoring using its NewSat constellation, marking a significant advancement in national-scale Earth observation [1][2] Group 1: Agreement Details - The contract extension is for 11 months and builds on a previous three-year agreement that provided dedicated satellite capacity and the naming of two satellites, Albania-1 and Albania-2 [2] - Under the new agreement, Albanian government agencies will receive high-resolution imagery (50 cm) covering the entire territory of Albania, facilitating persistent oversight and centralized intelligence [2][3] Group 2: Strategic Importance - This extension reflects Albania's commitment to proactive monitoring rather than reactive tasking, allowing for continuous detection of changes and anomalies across various use cases such as illegal construction and natural resource management [3] - The partnership emphasizes the need for continuous oversight by national governments, highlighting the operational necessity and economic viability of persistent monitoring [4] Group 3: Company Overview - Founded in 2010, Satellogic is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, providing decision-grade insights to government and commercial customers [5] - The company's integrated approach allows for predictable satellite deployment and persistent coverage, enabling proactive decision-making for defense, intelligence, and civil government agencies [6]

RA'ANANA, Israel, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that its U.S. Food and Drug Administration (the “FDA”)-cleared INSPIRA™ ART100 system has completed its full clinical evaluation and advanced to a budgeted procurement execution process at a leading U.S. academic medical center, ranked among the top hospitals in ...